# PhotoPharmics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/photopharmics

- Industry: Medical Devices & Equipment
- Headquarters: Lehi, US
- Website: www.photopharmics.com
- Total disclosed funding: $22M
- Latest round: Series B (Apr 18, 2025)
- Investors on record: 1

## About

PhotoPharmics Inc. is a US-based company dedicated to developing innovative phototherapy solutions for neurodegenerative diseases, notably Parkinson's disease, enhancing patients' quality of life through specialized treatment methods.PhotoPharmics, founded in 2011 in Lehi, US, focuses on creating therapeutic solutions for individuals with neurodegenerative diseases. The company is led by CEO Kent Savage and has raised a total of USD 6.00 mn through a Series B funding round led by Kickstart Capital on April 18, 2025.PhotoPharmics specializes in innovative health solutions aimed at improving the quality of life for individuals with neurodegenerative diseases, particularly Parkinson's disease (PD). The company's flagship product, Celeste® specialized phototherapy, is a non-invasive at-home device designed to address both motor and non-motor symptoms associated with PD. Through personalized light therapy, the device aims to alleviate issues such as sleep disorders, fatigue, and mood disturbances, which are common in PD patients. The company is currently conducting clinical trials, including the “Light-for-PD” trial, to substantiate the safety and efficacy of its therapeutic offerings. PhotoPharmics serves a global client base that includes healthcare providers and patients across various regions, with ongoing trials and potential market entries planned in North America and Europe.PhotoPharmics generates revenue through the commercialization of its specialized phototherapy products, which are positioned for prescription use by healthcare professionals. The company’s business model includes direct-to-consumer sales facilitated through partnerships with medical providers, allowing patients to access the Celeste® device as part of their treatment regimen. Revenue streams are expected to be bolstered by ongoing clinical trials that enhance product visibility and credibility within the healthcare community. Specific pricing information and transaction structures are tailored to accommodate healthcare providers and patients alike, ensuring accessibility and adherence to treatment protocols. As the company advances towards regulatory submission and market launch, it focuses on solidifying its position as a standard of care in the treatment of neurodegenerative diseases.In April 2025, PhotoPharmics, Inc. raised USD 6.00 mn in Series B funding led by returning investor Kickstart Capital to support the development of its Phase 3 clinical trial. The company plans to expand its product offerings and aims to enter new markets in North America and Europe by leveraging the recent funding to enhance clinical trial efforts and improve product visibility.

## Funding rounds

- Series B, Apr 18, 2025, $6M — Kickstart
- Series B, Oct 31, 2023, $16M — Kickstart

## Investors

- Kickstart (https://capitalatlas.ai/funds/kickstart) — Series B